Active Filter(s):
Details:
The new Agreement grants Acrotech a royalty-free license to belinostat in all other territories including the United States, Canada, Mexico, and India.
Lead Product(s): Belinostat
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Acrotech Biopharma
Deal Size: $6.6 million Upfront Cash: $6.6 million
Deal Type: Agreement April 06, 2020